CO6362012A2 - Clohidarto de nalmefeno dihidratado - Google Patents

Clohidarto de nalmefeno dihidratado

Info

Publication number
CO6362012A2
CO6362012A2 CO11067790A CO11067790A CO6362012A2 CO 6362012 A2 CO6362012 A2 CO 6362012A2 CO 11067790 A CO11067790 A CO 11067790A CO 11067790 A CO11067790 A CO 11067790A CO 6362012 A2 CO6362012 A2 CO 6362012A2
Authority
CO
Colombia
Prior art keywords
clohydrate
nalmefen
dihydrated
hydrochloride dihydrate
nalmefene hydrochloride
Prior art date
Application number
CO11067790A
Other languages
English (en)
Inventor
De Diego Heidi Lopez
Florian Anton Martin Huber
Faveri Carla De
Original Assignee
H Lundbeck As
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41571731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6362012(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As, Biotie Therapies Corp filed Critical H Lundbeck As
Publication of CO6362012A2 publication Critical patent/CO6362012A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere al clorhidrato de nalmefeno dihidratado, métodos de manufactura del clorhidrato de nalmefeno dihidratado, una composición farmacéutica que comprende clorhidrato de nalmefeno dihidratado y un método de tratamiento que comprende administrar clorhidrato de nalmefeno dihidratado.
CO11067790A 2008-12-05 2011-06-01 Clohidarto de nalmefeno dihidratado CO6362012A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200801729 2008-12-05

Publications (1)

Publication Number Publication Date
CO6362012A2 true CO6362012A2 (es) 2012-01-20

Family

ID=41571731

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11067790A CO6362012A2 (es) 2008-12-05 2011-06-01 Clohidarto de nalmefeno dihidratado

Country Status (31)

Country Link
US (2) US8530495B2 (es)
EP (2) EP2300479B1 (es)
JP (3) JP6055183B2 (es)
KR (2) KR20110089333A (es)
CN (2) CN102325778B (es)
AR (1) AR074507A1 (es)
AT (1) ATE546453T1 (es)
AU (1) AU2009321898B2 (es)
BR (1) BRPI0922774B8 (es)
CA (1) CA2744932C (es)
CL (1) CL2011001331A1 (es)
CO (1) CO6362012A2 (es)
CY (2) CY1112643T1 (es)
DK (2) DK2300479T3 (es)
EA (1) EA018948B1 (es)
ES (2) ES2488165T3 (es)
HK (1) HK1205108A1 (es)
HR (2) HRP20120247T1 (es)
IL (1) IL213112A (es)
MX (1) MX2011005865A (es)
MY (1) MY149028A (es)
NZ (1) NZ593874A (es)
PL (2) PL2300479T3 (es)
PT (2) PT2300479E (es)
RS (2) RS52255B (es)
SG (1) SG171910A1 (es)
SI (2) SI2300479T1 (es)
SM (2) SMT201200014B (es)
TW (1) TWI465450B (es)
UA (1) UA102128C2 (es)
WO (1) WO2010063292A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
JP2019031524A (ja) * 2008-12-05 2019-02-28 ハー・ルンドベック・アクチエゼルスカベット ナルメフェン塩酸塩二水和物
TWI560170B (en) * 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
AR090916A1 (es) 2012-05-03 2014-12-17 Lundbeck & Co As H Metodo para la fabricacion de naltrexona
US20140005216A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
JP6479766B2 (ja) * 2013-04-17 2019-03-06 ハー・ルンドベック・アクチエゼルスカベット 不安障害患者の治療のためのナルメフェン
JP6419780B2 (ja) * 2013-04-17 2018-11-07 ハー・ルンドベック・アクチエゼルスカベット 睡眠障害患者の治療のためのナルメフェン
AR096851A1 (es) 2013-07-11 2016-02-03 H Lundbeck As Sales que no forman hidratos ni solvatos de nalmefeno
WO2015163486A1 (en) 2014-04-22 2015-10-29 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
TWI729644B (zh) * 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN105646508B (zh) * 2016-02-17 2018-02-27 南京卓康医药科技有限公司 一种盐酸纳美芬一水合物的制备方法
WO2019022274A1 (ko) * 2017-07-28 2019-01-31 동아대학교 산학협력단 Pauf 단백질에 특이적으로 결합하는 항체 및 이의 용도
US10927121B1 (en) 2019-12-20 2021-02-23 Southwest Research Institute Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
CN111875530A (zh) * 2020-08-17 2020-11-03 浙江朗华制药有限公司 一种普拉西坦水合物晶体及其制备方法
WO2022165040A1 (en) 2021-01-28 2022-08-04 Rhodes Technologies Process for crystallizing nalmefene hydrochloride
CN113354652A (zh) * 2021-06-24 2021-09-07 无锡济煜山禾药业股份有限公司 一种盐酸纳美芬合成方法
CN117986261B (zh) * 2024-04-02 2024-06-18 成都瑞尔医药科技有限公司 一种盐酸纳美芬母液的回收套用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
CH693586A8 (de) * 2002-10-14 2003-12-15 Roche Consumer Health Ag Darreichungsform von Ibuprofen-Natrium.
FR2861299B1 (fr) * 2003-10-28 2006-01-27 Pf Medicament Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes
EP1708690B1 (en) * 2003-11-17 2016-07-20 BioMarin Pharmaceutical Inc. Treatment of phenylketonuria with bh4
MY139797A (en) * 2004-11-29 2009-10-30 Kowa Co (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1, 4-homopiperazine hydrochloride dihydrate
CN100536848C (zh) * 2005-07-13 2009-09-09 北京易明康元医药科技有限公司 稳定的盐酸纳美芬注射液及其制备方法
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
NZ580536A (en) * 2007-03-06 2010-11-26 Mallinckrodt Inc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
WO2008127618A1 (en) * 2007-04-12 2008-10-23 Mallinckrodt Inc. Crystalline and amorphous forms of naltrexone hydrochloride
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate

Also Published As

Publication number Publication date
ES2380297T3 (es) 2012-05-10
JP2012510954A (ja) 2012-05-17
DK2300479T3 (da) 2012-03-26
ES2488165T3 (es) 2014-08-26
HRP20120247T1 (hr) 2012-05-31
CY1112643T1 (el) 2016-02-10
US8754217B2 (en) 2014-06-17
BRPI0922774A2 (pt) 2017-07-11
SMT201200014B (it) 2012-07-10
PL2441766T3 (pl) 2014-09-30
EA018948B1 (ru) 2013-11-29
SMT201400113B (it) 2014-11-10
PL2300479T3 (pl) 2012-06-29
MX2011005865A (es) 2011-09-06
CN102325778B (zh) 2014-08-13
IL213112A0 (en) 2011-07-31
AU2009321898B2 (en) 2014-10-02
US20110251228A1 (en) 2011-10-13
TWI465450B (zh) 2014-12-21
US8530495B2 (en) 2013-09-10
CL2011001331A1 (es) 2011-08-26
JP6055183B2 (ja) 2016-12-27
EP2300479A1 (en) 2011-03-30
ATE546453T1 (de) 2012-03-15
CN104211707B (zh) 2017-04-12
SI2300479T1 (sl) 2012-07-31
AU2009321898A1 (en) 2011-07-14
PT2441766E (pt) 2014-08-05
IL213112A (en) 2013-06-27
JP6591944B2 (ja) 2019-10-16
KR20110089333A (ko) 2011-08-05
JP2017025079A (ja) 2017-02-02
CY1115381T1 (el) 2017-01-04
SG171910A1 (en) 2011-07-28
BRPI0922774B8 (pt) 2021-05-25
HK1205108A1 (en) 2015-12-11
JP6591759B2 (ja) 2019-10-16
DK2441766T3 (da) 2014-07-21
WO2010063292A1 (en) 2010-06-10
EP2441766A1 (en) 2012-04-18
AR074507A1 (es) 2011-01-19
PT2300479E (pt) 2012-04-10
US20130338365A1 (en) 2013-12-19
RS52255B (en) 2012-10-31
EA201170753A1 (ru) 2011-12-30
TW201022273A (en) 2010-06-16
EP2441766B1 (en) 2014-06-25
JP2015134785A (ja) 2015-07-27
CA2744932C (en) 2013-05-07
CN104211707A (zh) 2014-12-17
SI2441766T1 (sl) 2014-12-31
NZ593874A (en) 2013-02-22
UA102128C2 (en) 2013-06-10
HRP20140648T1 (hr) 2014-09-26
CN102325778A (zh) 2012-01-18
MY149028A (en) 2013-06-28
BRPI0922774B1 (pt) 2020-10-13
RS53415B (en) 2014-12-31
CA2744932A1 (en) 2010-06-10
KR20170008893A (ko) 2017-01-24
EP2300479B1 (en) 2012-02-22

Similar Documents

Publication Publication Date Title
CO6362012A2 (es) Clohidarto de nalmefeno dihidratado
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
ECSP12011930A (es) Nuevos compuestos de espiropiperidina
UA106748C2 (uk) Похідні проліну як інгібітори катепсину
EA201001639A1 (ru) Композиции и способы их получения и применения
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
EA200802324A1 (ru) Новая форма введения рацекадотрила
MX2011012993A (es) Bencimidazoles, benzotiazoles y benzoxazoles, sustituidos.
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
CO6400219A2 (es) Derivados de ciclopropilamida dirigidos al receptor h3 de la histamina
EA201190312A1 (ru) Замещенные пиперидины
CL2010000281A1 (es) Formulacion oral en forma de tableta de 9-[(2,2-dimetil-propilamino)-metil]-minociclina; metodo de preparacion; formulacion inyectable del mismo; utiles en el tratamiento de una infeccion.
BRPI0919694A2 (pt) composto, composto farmacêutica, uso de um composto, e, método de tratamento de uma doença.
EA200970816A1 (ru) Новая лекарственная форма
UY32507A (es) Una dosis de ave5026 para el tratamiento de trombormbolismo venoso en pacientes con deterioro renal severo
GB201022049D0 (en) Methods
BR112012000262A2 (pt) composição farmacêutica, e, método de tratamento de uma condição.
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
CL2011002444A1 (es) Composicion farmaceutica que contiene un liposoma y el compuesto activo eribulina o su sal farmacologicamente permisible en la fase interna del liposoma; y el metodo de manufactura de la composicion de liposoma.
BRPI0820210A2 (pt) composto, composição farmacêutica, uso de um composto, e, método de tratamento terapêutico de um mamífero.
MX2011005054A (es) Uso combinado de bendamustina, doxorubicina y bortezomib para el tratamiento del mieloma multiple.

Legal Events

Date Code Title Description
FC Application refused